Company Overview of VaxInnate, Inc.
VaxInnate, Inc., a biotechnology company, engages in the development and production of vaccines for pandemic and seasonal influenza diseases. Its products include Flagellin.HuHA and flagellin.AvHA, which are fusion proteins linking a potent immune stimulator, the bacterial protein flagellin, with immunoprotective domain of viral hemagglutinin. The company's products are used in the treatment of various diseases, including bacterial, viral, and parasitic infections. VaxInnate, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
3 Cedar Brook Drive
Cranbury, NJ 08512
Founded in 2002
Key Executives for VaxInnate, Inc.
Chief Executive Officer, President and Director
Vice President of Business Development
Compensation as of Fiscal Year 2014.
VaxInnate, Inc. Key Developments
VaxInnate, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:00 AM
Mar 25 15
VaxInnate, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 10:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Wayne F. Pisano, Chief Executive Officer, President and Director.
VaxInnate Corporation Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
Dec 8 14
VaxInnate Corporation announced the initiation of a double-blind, randomized, placebo-controlled Phase 1b/2 study of VAX2012Q in healthy adults 65-75 years of age. VAX2012Q is the company's seasonal quadrivalent influenza vaccine candidate, which incorporates a bacterial flagellin protein designed to enhance the adaptive immune response to the vaccine. This Phase 1b/2 study will evaluate the vaccine's safety and immunogenicity in this elderly population. The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, has funded the production of VAX2012Q for use in this clinical study under contract No. HHSO100201100011C. VAX2012Q is comprised of four seasonal influenza strains, each fused to a flagellin protein, which acts as a toll-like receptor (TLR) ligand. The TLR class of proteins is known to activate the innate immune system, which in turn enhances the adaptive immune response to vaccines. In a previous clinical study, VAX125, a vaccine comprised of one seasonal influenza H1N1 strain, was shown to elicit a robust immune response in the elderly. This Phase 1b/2 study will enroll up to 200 healthy adults 65-75 years of age, who will be administered either VAX2012Q or placebo. In addition to safety, which is the trial's primary objective, the study will also assess the dose levels necessary to produce a robust immune response in the majority of study participants. Individuals will be monitored for one year following their vaccination to assess long-term safety.
VaxInnate Updates Plans to Advance Lead Vaccine Candidate, VAX2012Q in Elderly
Oct 8 14
VaxInnate Corporation provided an update on clinical development plans for the Company’s experimental recombinant quadrivalent vaccine, VAX2012Q. VaxInnate plans to advance VAX2012Q into a Phase 1b/2 study for the prevention of seasonal influenza in elderly individuals by the end of 2014. Up to 200 healthy adults age 65-75 years will be enrolled in this multi-center, randomized, double-blind, placebo-controlled, dose-escalating Phase 1b/2 study. VAX2012Q was also assessed in a Phase 1 study in adults 18-40 years of age initiated in March 2014. This Phase 1 study was the subject of an abstract accepted at the recent Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and showed that doses up to 18 mcg were generally well tolerated and immunogenic with mild to moderate arm pain as the most common adverse event reported.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 25, 2014